AIFA: Autorizzazione all’immissione in commercio del medicinale per uso umano, a base di Liraglutide, «Diavic», in apposita sezione denominata classe C
20/01/2025
Leggi
Breaking news
AIFA: Classificazione, in apposita sezione denominata classe C, del medicinale per uso umano a base di semaglutide «Rybelsus» 25 mg e 50 mg (Determina n. 788/2024)
20/01/2025
Leggi
Barriers and new opportunities in developing effective therapies for diabetic neuropathy: international expert consensus recommendations
Brock C, Andersen H, Alibegovic AC, et al.
Diabetes Res Clin Pract. 2025:112010.
Leggi
Glucose Lowering through Weight management (GLoW): a randomised controlled trial of the clinical and cost effectiveness of a diabetes education and behavioural weight management programme vs a diabetes education programme in adults with a recent diagnosis of type 2 diabetes
Mueller J, Breeze P, Fusco F, et al.
Diabetologia. Pub. online 23 Jan 2025.
Leggi
Risk of renal complications and death in young and middle-aged Swedes with parental type 1 diabetes: a nation-wide, prospective cohort study
Fredriksson M, Persson E, Möllsten A, Lind T
BMJ Open Diabetes Res Care. 2025;13(1):e004709.
Leggi
Comparative effectiveness of individual sodium-glucose cotransporter 2 inhibitors
Shin H, Paik JM, Everett BM, et al.
JAMA Intern Med. Pub. online 21 Jan 2025.
Leggi
Active targeting of type 1 diabetes therapies to pancreatic beta cells using nanocarriers
Collins J, Farnsworth NL
Diabetologia. Pub. online 23 Jan 2025.
Abstract
Leggi
Semaglutide in obesity-related heart failure with preserved ejection fraction and type 2 diabetes across baseline HbA1c levels (STEP-HFpEF DM): a prespecified analysis of heart failure and metabolic outcomes from a randomised, placebo-controlled trial
Davies MJ, van der Meer P, Verma S, Patel S, et al.
Lancet Diabetes Endocrinol. Pub. online 20 Jan 2025.
Leggi
Effectiveness of empagliflozin vs dapagliflozin for kidney outcomes in type 2 diabetes
Bonnesen K, Heide-Jørgensen U, Christensen DH
JAMA Intern Med. Pub. online 21 Jan 2025.
Leggi
Association between use of sodium-glucose co-transporter-2 inhibitor and the risk of incident dementia: a population-based cohort study
Abdullah Z, Cui Y, Platt RW, et al.
BMJ Open Diabetes Res Care. 2025;13(1):e004541.
Leggi